Tyra Biosciences’ Abstracts Accepted for Presentation at ASCO GI Symposium
Carlsbad, CA, January 22, 2025 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a pioneering clinical-stage biotechnology company, announced recently that two abstracts from its ongoing research in Fibroblast Growth Factor Receptor (FGFR) biology have been accepted for presentation at the prestigious 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), scheduled for January 23-25, 2025, in San Francisco, CA.
About Tyra Biosciences and FGFR Biology
Tyra Biosciences is dedicated to advancing the field of precision medicine through the development of next-generation therapeutics that target FGFR biology. FGFRs are a family of receptor tyrosine kinases (RTKs) involved in cell growth, survival, and differentiation. Dysregulation of FGFR signaling is implicated in several cancers, including gastrointestinal cancers. Tyra Biosciences’ innovative approach focuses on developing small molecule inhibitors that selectively target these receptors, offering potential benefits over existing treatments.
Accepted Abstracts
The first accepted abstract, titled “Phase 1 Study of TYR-012 in Solid Tumors: Safety, Pharmacokinetics, and Preliminary Antitumor Activity,” will provide insights into the safety, pharmacokinetics, and preliminary antitumor activity of TYR-012, Tyra Biosciences’ lead small molecule FGFR inhibitor, in patients with advanced solid tumors. The second abstract, titled “A Phase 1b Study of TYR-012 in Combination with FOLFOX in Advanced Gastroesophageal Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma,” will discuss the safety, tolerability, and preliminary antitumor activity of TYR-012 in combination with FOLFOX (Folinic acid, 5-Fluorouracil, and Oxaliplatin), a standard chemotherapy regimen, in patients with advanced gastroesophageal adenocarcinoma and gastroesophageal junction adenocarcinoma.
Impact on Patients
The acceptance of these abstracts at the ASCO GI Symposium underscores the potential of Tyra Biosciences’ innovative approach to addressing the unmet needs in gastrointestinal cancers. For patients diagnosed with advanced gastrointestinal cancers, the development of new, more effective, and less toxic treatment options is crucial. The presentation of these abstracts offers a glimpse into the progress being made in the field and the potential for improved treatment outcomes.
Impact on the World
Beyond the direct impact on patients, the acceptance of these abstracts at ASCO GI also represents a significant step forward for Tyra Biosciences and the broader biotechnology industry. This achievement highlights the company’s commitment to advancing the field of precision medicine and the potential of its next-generation FGFR inhibitors. Furthermore, the data presented at the symposium could influence future clinical trials and collaborations, potentially leading to new treatment options for patients with gastrointestinal cancers and other FGFR-driven diseases.
Conclusion
In conclusion, the acceptance of two Tyra Biosciences abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium marks an essential milestone in the company’s mission to develop next-generation precision medicines targeting FGFR biology. The potential implications for patients with gastrointestinal cancers and the broader biotechnology industry are significant, offering hope for improved treatment outcomes and advancements in the field of precision medicine. The presentation of these abstracts at the prestigious ASCO GI Symposium is a testament to Tyra Biosciences’ dedication and innovation in the pursuit of new therapeutic solutions.
